Clinical Trials Browser

Carcinoma, Transitional Cell × ALX148 × Clear all

NCT05524545 2025-07-25

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase 1 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell